Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study

[1]  A. Vaag,et al.  Insulin Signal Transduction in Skeletal Muscle From Glucose-Intolerant Relatives With Type 2 Diabetes , 2001 .

[2]  P. Damsbo,et al.  Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. , 2001, Diabetes care.

[3]  J. Holst,et al.  Assessment of hepatic insulin action in obese type 2 diabetic patients. , 2001, Diabetes.

[4]  M. Iotti,et al.  Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes. , 2000, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[5]  J. Holst,et al.  Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. , 2000, Diabetes.

[6]  R. Bergman,et al.  Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. , 2000, Diabetes.

[7]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[8]  J. Holst,et al.  Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. , 1999, Diabetes care.

[9]  R R Wing,et al.  Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. , 1999, Diabetes.

[10]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[11]  E. Kraegen,et al.  The Determinants of Glycemic Responses to Diet Restriction and Weight Loss in Obesity and NIDDM , 1998, Diabetes Care.

[12]  N. Greig,et al.  Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. , 1997, The Journal of clinical investigation.

[13]  S. Bloom,et al.  Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus , 1997, European journal of clinical investigation.

[14]  G. Boden.  Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM , 1997, Diabetes.

[15]  J. Holst,et al.  Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM , 1996, Diabetologia.

[16]  J. Levy,et al.  Normalization of Insulin Responses to Glucose by Overnight Infusion of Glucagon-Like Peptide 1 (7–36) Amide in Patients With NIDDM , 1996, Diabetes.

[17]  D. Chisholm,et al.  Abdominal Fat and Insulin Resistance in Normal and Overweight Women: Direct Measurements Reveal a Strong Relationship in Subjects at Both Low and High Risk of NIDDM , 1996, Diabetes.

[18]  J. Holst,et al.  Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.

[19]  J. Holst,et al.  Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships , 1995, Diabetologia.

[20]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[21]  G A Colditz,et al.  Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men , 1994, Diabetes Care.

[22]  J. Holst,et al.  Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[23]  R. Henry,et al.  Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial , 1993, Diabetes Care.

[24]  D. Porte.  β-cells in type II diabetes mellitus , 1991, Diabetes.

[25]  R. DeFronzo,et al.  Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. , 1989, The American journal of physiology.

[26]  E. Kraegen,et al.  Physiological Importance of Deficiency in Early Prandial Insulin Secretion in Non-Insulin-Dependent Diabetes , 1988, Diabetes.

[27]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[28]  S. Lillioja,et al.  Increased Resting Metabolic Rates in Obese Subjects with Non-insulin-dependent Diabetes Mellitus and the Effect of Sulfonylurea Therapy , 1986, Diabetes.

[29]  J. Halter,et al.  Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. , 1984, The Journal of clinical investigation.

[30]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.

[31]  A. Astrup,et al.  Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies , 2000, International Journal of Obesity.

[32]  S. Bloom,et al.  Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. , 1999, Diabetes.

[33]  J. Holst,et al.  Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. , 1996, The Journal of clinical endocrinology and metabolism.

[34]  R. Holman,et al.  United Kingdom Prospective Diabetes Study 17: A 9-Year Update of a Randomized, Controlled Trial on the Effect of Improved Metabolic Control on Complications in Non-Insulin-dependent Diabetes Mellitus , 1996, Annals of Internal Medicine.